Literature DB >> 24775713

The prevalence of opportunistic infections and malignancies in autopsied patients with human immunodeficiency virus infection in Japan.

Harutaka Katano1, Tsunekazu Hishima, Makoto Mochizuki, Yoshinori Kodama, Naoki Oyaizu, Yasunori Ota, Sohtaro Mine, Toru Igari, Atsushi Ajisawa, Katsuji Teruya, Junko Tanuma, Yoshimi Kikuchi, Tomoko Uehira, Takuma Shirasaka, Tomohiko Koibuchi, Aikichi Iwamoto, Shinichi Oka, Hideki Hasegawa, Seiji Okada, Akira Yasuoka.   

Abstract

BACKGROUND: Opportunistic infections and malignancies such as malignant lymphoma and Kaposi sarcoma are significant complications of human immunodeficiency virus (HIV) infection. However, following the introduction of antiretroviral therapy in Japan in 1997, the incidence of clinical complications has decreased. In the present study, autopsy cases of HIV infection in Japan were retrospectively investigated to reveal the prevalence of opportunistic infections and malignancies.
METHODS: A total of 225 autopsy cases of HIV infection identified at 4 Japanese hospitals from 1985-2012 were retrospectively reviewed. Clinical data were collected from patient medical records.
RESULTS: Mean CD4 counts of patients were 77.0 cells/μL in patients who received any antiretroviral therapy during their lives (ART (+) patients) and 39.6 cells/μL in naïve patients (ART (-) patients). Cytomegalovirus infection (142 cases, 63.1%) and pneumocystis pneumonia (66 cases, 29.3%) were the most frequent opportunistic infections, and their prevalence was significantly lower in ART (+) patients than ART (-) patients. Non-Hodgkin lymphoma and Kaposi sarcoma were observed in 30.1% and 16.2% of ART (-) patients, and 37.9% and 15.2% of ART (+) patients, respectively. Malignant lymphoma was the most frequent cause of death, followed by cytomegalovirus infection regardless of ART. Non-acquired immunodeficiency syndrome (AIDS)-defining cancers such as liver and lung cancer caused death more frequently in ART (+) patients (9.1%) than in ART (-) patients (1.5%; P = 0.026).
CONCLUSIONS: The prevalence of infectious diseases and malignancies were revealed in autopsy cases of HIV infection in Japan. The prevalence of cytomegalovirus infection and pneumocystis pneumonia at autopsy were lower in ART (+) patients than ART (-) patients. Higher prevalence of non-AIDS defining malignancies among ART (+) patients than ART (-) patients suggests that onsets of various opportunistic infections and malignancies should be carefully monitored regardless of whether the patient is receiving ART.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24775713      PMCID: PMC4016795          DOI: 10.1186/1471-2334-14-229

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


Background

Opportunistic infections such as Pneumocystis jirovecii pneumonia (PCP), cytomegalovirus (CMV), non-tuberculous mycobacteria (NTM), and fungal infections are frequently found in patients with acquired immunodeficiency syndrome (AIDS) [1]. The most frequent opportunistic infection among patients with AIDS is CMV infection, which commonly causes retinitis, pneumonia, and gastrointestinal tract ulcers. PCP is also a frequent infectious disease in the lungs of patients with AIDS. Additionally, malignancies such as non-Hodgkin lymphoma (NHL) and Kaposi sarcoma (KS) are significant complications. NHL in particular is not easily controlled and is a frequent AIDS-associated cause of death. Interestingly, KS has only been reported in homosexual patients, and patients with multifocal KS lesions have a poor prognosis. The introduction of antiretroviral therapy (ART) has drastically changed the incidence of opportunistic infections in patients infected with human immunodeficiency virus 1 (HIV-1), resulting in a decline in mortality rates [2-7]. ART has decreased the frequencies of CMV, PCP, and NTM infections in patients with AIDS [7]; however, the frequency of NHL has not changed dramatically [8]. Additionally, non-AIDS-defining malignancies such as liver, lung, and gastric cancers have been observed in patients with AIDS, regardless of ART [9]. A recent study demonstrated that low CD4 counts at ART initiation was associated with a greater risk of KS and lymphoma, whereas other cancers increased over time with ART, likely reflecting an increased risk of cancer with aging [10], low CD4 counts, and cigarette smoking [11-13]. Although mortality rates have decreased dramatically with the use of ART, its effect in many patients with AIDS is limited, and AIDS-associated complications remain a leading cause of death [14,15]. Additionally, untreated HIV-1-positive patients with severe AIDS-defining illnesses frequently visit hospitals and often rapidly succumb to suddenly aggressive progression of their illness [16,17]. Systematic pathological analysis of autopsy cases can provide useful information related to the cause of death and the distribution of pathogens in patients. However, there have been few reports describing the prevalence of infectious diseases and malignancies in autopsied patients with HIV infection [1,18]. A previous study using samples from autopsied patients with HIV infection during 1982–1998 demonstrated the prevalence of CMV, PCP, and NTM infections decreased during the study period [18]. The same study reported that, although the prevalence of KS was unchanged, the prevalence of NHL increased during the study period [18]. To the best of our knowledge, there are no reports demonstrating changes in the prevalence of opportunistic infections in autopsy cases of HIV infection following the introduction of ART after 2000. In the present study, autopsy cases of HIV infection in Japan were retrospectively investigated to determine the prevalence of opportunistic infections and malignancies often found in patients with AIDS, including non-AIDS-defining malignancies. Additionally, the association of ART use with the prevalence of opportunistic infections and malignancies was investigated.

Patients and methods

Patients

The present study was approved by the Institutional Review Board of the National Institute of Infectious Diseases (Approval No. 356) and of four hospitals in Japan: Tokyo Metropolitan Komagome Hospital, National Center for Global Health and Medicine, Research Hospital, the Institute of Medical Science, the University of Tokyo, and Osaka National Hospital. Each hospital enrolled in the present study is a central hospital for AIDS treatment in Tokyo and Osaka, and has performed more than 15 autopsies of patients infected with HIV. According to a national autopsy survey by the Japan Pathology Society, 828 patients infected with HIV were autopsied in Japan from 1987–2009. During the period 1985–2009, 215 patients infected with HIV were autopsied at the 4 aforementioned hospitals. Thus, the number of cases in this study covered approximately 26% of all autopsied HIV cases. Ten cases autopsied in the period 2010–2012 were added to the 215 cases, making a total of 225 patients analyzed in this study (Table  1), of which 95.1% were male. The patients’ ages at death ranged from 12 to 80 years, with a mean age of 44.4 years (median 44 years). Among them, 35.6% were homosexual, and 29.3% received ART (Table  1). The mean CD4 count at the last blood examination before death was 51.5 cells/μL (range: 0–560 cells/μL; median: 13.5 cells/μL). ART was introduced in Japan in 1997. In this study, ART was defined as any combination of therapy that included two nucleoside or nucleotide reverse transcriptase inhibitors plus a non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or abacavir (another nucleotide reverse transcriptase inhibitor). Additionally, ART (+) patients were defined as patients who received any ART during their lifetime, whereas ART (−) patients were as patients who did not receive ART.
Table 1

Characteristics of the patients infected with HIV

Factors
Groupings
Total patients
ART (−) patients
ART (+) patients
P value
  n%n%n% 
Total
 
225*
100%
136
100%
66
100%
 
Sex
Male
214
95.1%
128
94.1%
63
95.5%
0.695**
 
Female
11
4.9%
8
5.9%
3
4.5%
 
Age at death
<10 years
0
0.0%
0
0.0%
0
0.0%
0.028***
 
11–20
2
0.9%
2
1.5%
0
0.0%
 
 
21–30
30
13.3%
22
16.2%
6
9.1%
 
 
31–40
60
26.7%
34
25.0%
19
28.8%
 
 
41–50
69
30.7%
48
35.3%
14
21.2%
 
 
51–60
34
15.1%
18
13.2%
14
21.2%
 
 
61–70
24
10.7%
10
7.4%
10
15.2%
 
 
71–80
5
2.2%
1
0.7%
3
4.5%
 
 
>81
0
0.0%
0
0.0%
0
0.0%
 
 
Unknown
1
0.4%
1
0.7%
0
0.0%
 
Risk factor
Homosexual
80
35.6%
52
38.2%
24
36.4%
0.800**
 
Heterosexual
38
16.9%
24
17.6%
10
15.2%
 
 
Blood product
37
16.4%
29
21.3%
7
10.6%
 
 
Other
9
4.0%
5
3.7%
4
6.1%
 
 
Unknown
61
27.1%
26
19.1%
21
31.8%
 
CD4 count before death
<50 cells/μL
122
54.2%
80
58.8%
33
50.0%
0.639***
51–100
25
11.1%
11
8.1%
14
21.2%
 
101–200
13
5.8%
4
2.9%
9
13.6%
 
201–300
5
2.2%
5
3.7%
0
0.0%
 
301–400
3
1.3%
1
0.7%
2
3.0%
 
>401
4
1.8%
1
0.7%
3
4.5%
 
 Unknown5323.6%3425.0%57.6% 

ART, antiretroviral therapy. ART (+) patients were defined as patients who received any ART during their lifetime, whereas ART (−) patients were as patients who did not receive any ART in their lifetime.

*Total number of patients = 225 and included 23 patients with unknown ART status.

**P values were calculated for the rates of male or homosexuals between ART (−) and (+) patients by Chi-square test.

***P values were calculated for age or CD4 counts between all ART (−) and (+) patients by Mann–Whitney U-test. Bold font indicates statistical significance.

Characteristics of the patients infected with HIV ART, antiretroviral therapy. ART (+) patients were defined as patients who received any ART during their lifetime, whereas ART (−) patients were as patients who did not receive any ART in their lifetime. *Total number of patients = 225 and included 23 patients with unknown ART status. **P values were calculated for the rates of male or homosexuals between ART (−) and (+) patients by Chi-square test. ***P values were calculated for age or CD4 counts between all ART (−) and (+) patients by Mann–Whitney U-test. Bold font indicates statistical significance.

Methods

Pathological findings were collected from autopsy records. CMV infection was determined by the infiltration of large cells with typical inclusion bodies. Infections by other viral agents such as hepatitis B virus, herpes simplex virus, hepatitis C virus, JC virus (causing progressive multifocal leukoencephalopathy), and varicella zoster virus were confirmed by immunohistochemistry or polymerase chain reaction. HIV encephalopathy was defined by morphological features indicating the presence of syncytial giant cells and detection of HIV-1 antigen by immunohistochemistry in the brain. Bacterial infection was identified by Gram stain, and in some cases, species of bacteria were identified by bacterial cultures. Tuberculosis and NTM infection were determined by acid-fast stain and/or PCR. Fungal and protozoan infections such as PCP, toxoplasma, Candida, Aspergillus, and Cryptococcus infection, were determined morphologically using Grocott’s methenamine silver stain, periodic acid-Schiff stain, or/and immunohistochemistry. The histological sub-typing of malignant lymphoma was based on the World Health Organization classification, fourth edition. KS was confirmed by immunohistochemistry for Kaposi sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen 1. Causes of death were determined by pathologists at each hospital based on the severity, distribution, and type of illness in the pathological findings of autopsy. Clinical data, such as age at autopsy, sex, risk factors, CD4 cell counts at the last blood examination before death, and use of ART in their lifetime were collected from medical records. Analysis of statistical significance was carried out using Mann–Whitney U-test for non-parametric two-sample analysis and Chi-squared test for contingency table analysis.

Results

After the introduction of ART in Japan in 1997, the total number of autopsies conducted on patients with HIV infection has slowly decreased whereas the mean age at autopsy has increased slightly (Figure  1). After 1997, 66 of 126 patients (52.6%) received ART during their lifetime. The mean age at death of patients on ART was 47.3 years, which was significantly higher than that of ART naïve patients (42.6 years; P = 0.028; Mann–Whitney U-test). Mean CD4 counts of ART (−) and (+) patients at the last blood examination before death were not significantly different (39.6 and 77.0 cells/μL, respectively, P = 0.63, Mann–Whitney U-test).
Figure 1

Annual number and mean age of AIDS-related autopsies. The solid line indicates total number of AIDS autopsies in each year. The gray area indicates the number of patients on ART in these autopsy cases. The broken bar indicates the mean age.

Annual number and mean age of AIDS-related autopsies. The solid line indicates total number of AIDS autopsies in each year. The gray area indicates the number of patients on ART in these autopsy cases. The broken bar indicates the mean age. CMV was the most commonly identified pathogen among the autopsy cases (Table  2) and was detected in various organs, the most frequent being the adrenal gland (Figure  2A). PCP and NTM were also common pathogens found in the lungs of autopsied patients. Candida albicans was frequently detected in the gastrointestinal tract and oral cavity (Figure  2B). The prevalence of CMV and PCP was significantly lower in ART (+) patients than in ART (−) patients (Table  2). There was no significant difference in the prevalence of other opportunistic infections such as NTM and Candida or prevalence of HIV encephalopathy between ART (+) and (−) patients (Table  2).
Table 2

Infectious diseases and malignancies in AIDS-associated autopsies

 
All patients
ART (−) patients
ART (+) patients
 
 
 n%n%n%P values 
Total
225
100.0%
136
100.0%
66
100.0%
 
 
Infectious diseases
 
 
 
 
 
 
 
 
  Cytomegalovirus
142
63.1%
97
71.3%
25
37.9%
<0.001
 
  Pneumocystis jirovecii pneumonia
66
29.3%
43
31.6%
11
16.7%
0.024
 
  Non-tuberculous mycobacterium
31
13.8%
20
14.7%
8
12.1%
0.618
 
  Candida
25
11.1%
17
12.5%
6
9.1%
0.474
 
  Aspergillus
24
10.7%
17
12.5%
4
6.1%
0.160
 
  Human immunodeficiency virus encephalopathy
21
9.3%
13
9.6%
6
9.1%
0.915
 
  Cryptococcus
16
7.1%
11
8.1%
3
4.5%
0.526
Y
  Hepatitis B virus
12
5.3%
6
4.4%
5
7.6%
0.549
Y
  Herpes simplex virus
12
5.3%
1
0.7%
1
1.5%
0.816
Y
  Toxoplasmosis
11
4.9%
9
6.6%
3
4.5%
0.789
Y
  Hepatitis C virus
9
4.0%
3
2.2%
5
7.6%
0.147
Y
  Progressive multifocal leukoencephalopathy
8
3.6%
4
2.9%
2
3.0%
0.684
Y
  Tuberculosis
6
2.7%
4
2.9%
0
0.0%
0.385
Y
  Varicella zoster virus
4
1.8%
2
1.5%
2
3.0%
0.835
Y
  Multicentric Castleman disease
2
0.9%
1
0.7%
1
1.5%
0.816
Y
Malignancies
 
 
 
 
 
 
 
 
  Non Hodgkin lymphoma
71
31.6%
41
30.1%
25
37.9%
0.272
 
  Kaposi sarcoma
38
16.9%
22
16.2%
10
15.2%
0.852
 
  Endocervical cancer
0
0.0%
0
0.0%
0
0.0%

 
  Non-AIDS defining malignancies
20
8.9%
10
7.4%
10
15.2%
0.082
 
   Hepatic cancer
8
3.6%
4
2.9%
4
6.1%
0.495
Y
   Lung cancer
6
2.7%
2
1.5%
4
6.1%
0.174
Y
   Leukemia
2
0.9%
0
0.0%
2
3.0%
0.200
Y
   Hodgkin lymphoma
2
0.9%
1
0.7%
1
1.5%
0.816
Y
   Gastric cancer
1
0.4%
1
0.7%
0
0.0%
0.711
Y
   Other cancer31.3%32.2%00.0%0.551Y

P values were calculated by Chi-square test. Y indicates the use of Chi-square test with Yates correction. Bold font indicates statistical significance. ART, antiretroviral therapy. Because more than one illness was detected in patients, the numbers of all illness are greater than the total number.

Figure 2

Distribution of cytomegalovirus and . (A) CMV positive rate in each organ. Black bar indicates the CMV positive rate in each organ from 142 CMV-positive patients. Because CMV was detected in more than one organ per patient, the sum of the black bars is over 100%. (B) The positive rate of Candida albicans in each organ. Black bar indicates the positive rate of Candida albicans per organ from 25 Candida albicans-positive patients.

Infectious diseases and malignancies in AIDS-associated autopsies P values were calculated by Chi-square test. Y indicates the use of Chi-square test with Yates correction. Bold font indicates statistical significance. ART, antiretroviral therapy. Because more than one illness was detected in patients, the numbers of all illness are greater than the total number. Distribution of cytomegalovirus and . (A) CMV positive rate in each organ. Black bar indicates the CMV positive rate in each organ from 142 CMV-positive patients. Because CMV was detected in more than one organ per patient, the sum of the black bars is over 100%. (B) The positive rate of Candida albicans in each organ. Black bar indicates the positive rate of Candida albicans per organ from 25 Candida albicans-positive patients. Malignancies were identified in 50.2% (113/225) of all cases (Table  2). NHL was the most frequent malignancy with a lower prevalence in ART (−) patients (30.1%) than ART (+) patients (37.9%); however, the difference was not significant (Table  2). Diffuse large B-cell lymphoma was the most frequent histological subtype of NHL followed by Burkitt lymphoma, primary effusion lymphoma, and plasmablastic lymphoma (Table  3). Epstein–Barr virus positivity in lymphoma cases was significantly lower in ART (+) patients compared with ART (−) patients (P = 0.001, Chi-square test). KS was frequently found in the skin as well as other sites such as the gastrointestinal tract upon autopsy. In addition to NHL and KS, non-AIDS-defining malignancies such as Hodgkin lymphoma (HL), hepatic cancer, lung cancer, and leukemia were also observed in 20 patients. The prevalence of non-AIDS-defining malignancies was higher in ART (+) patients compared with ART (−) patients (Table  2).
Table 3

Non-Hodgkin lymphoma and Kaposi sarcoma in AIDS-associated autopsies

 
 
Total
ART (−) patients
ART (+) patients
P values
  n%n%n%  
All NHL cases
 
71
100.0%
41
100.0%
25
100.0%
 
 
 Histology
DLBCL
53
74.6%
30
73.2%
18
72.0%
0.917
 
 
BL
4
5.6%
3
7.3%
1
4.0%
0.987
Y
 
PEL
5
7.0%
4
9.8%
1
4.0%
0.706
Y
 
PBL
1
1.4%
1
2.4%
0
0.0%
0.801
Y
 
Other
6
8.5%
2
4.9%
4
16.0%
0.279
Y
 
Unknown
2
2.8%
1
2.4%
1
4.0%
0.703
Y
 Site
Nodular
1
1.4%
0
0.0%
1
4.0%
0.801
Y
 
Extranodular
45
63.4%
28
68.3%
12
48.0%
0.102
 
 
Both
21
29.6%
11
26.8%
10
40.0%
0.265
 
 
Unknown
4
5.6%
2
4.9%
2
8.0%
0.987
Y
 PCNS
Yes
27
38.0%
18
43.9%
6
24.0%
0.103
 
 EBV
Positive
52
73.2%
35
85.4%
12
48.0%
0.001
 
 KSHV
Positive
6
8.5%
5
12.2%
1
4.0%
0.495
Y
 Cause of death
Yes
50
70.4%
33
80.5%
16
64.0%
0.137
 
All KS cases
 
38
 
22
 
10
 
 
 
 Site
Skin
32
84.2%
19
86.4%
9
90.0%
0.410
 
 
GI tract
27
71.1%
15
68.2%
8
80.0%
0.705
 
 
Lung
21
55.3%
11
50.0%
6
60.0%
0.799
 
 
Lymph node
20
52.6%
13
59.1%
6
60.0%
0.502
 
 
Other
16
42.1%
0
0.0%
0
0.0%
0.787
Y
 Cause of deathYes1129.0%731.8%220.0%0.791Y

NHL, Non-Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma; BL, Burkitt lymphoma; PEL, primary effusion lymphoma; PBL, plasmablastic lymphoma; PCNS, primary central nervous system lymphoma; EBV, Epstein–Barr virus; KSHV, Kaposi sarcoma-associated herpes virus; KS, Kaposi sarcoma; GI, gastrointestinal. P values were calculated by Chi-square test. Y indicates the use of Chi-square test with Yates correction. Bold font indicates statistical significance.

Non-Hodgkin lymphoma and Kaposi sarcoma in AIDS-associated autopsies NHL, Non-Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma; BL, Burkitt lymphoma; PEL, primary effusion lymphoma; PBL, plasmablastic lymphoma; PCNS, primary central nervous system lymphoma; EBV, Epstein–Barr virus; KSHV, Kaposi sarcoma-associated herpes virus; KS, Kaposi sarcoma; GI, gastrointestinal. P values were calculated by Chi-square test. Y indicates the use of Chi-square test with Yates correction. Bold font indicates statistical significance. The lung was the most frequent target for pathogens in patients with AIDS and 173 (76.9%) autopsy cases demonstrated the presence of lung-related illnesses (Table  4), which were significantly more frequent in ART (−) patients (112/136, 82.4%) than ART (+) patients (42/66, 63.6%) (P = 0.003, Chi-square test). CMV then PCP was the most frequently observed lung-related illnesses. The brain was the second most frequently affected organ in the autopsy cases. Although the brain was not investigated in 53 autopsies, 85 of the remaining 172 cases (49.4%) had brain-related illnesses, with CMV infection the most common, followed by lymphoma and HIV encephalopathy (Table  5). However, there was no significant difference in the rate of brain-related illnesses in ART (+) (37.8%, 17 of 45) or ART (−) patients (52.7%, 58/110) (P = 0.091, Chi-square test).
Table 4

Lung disease in patients infected with HIV

Illness
n
% of total patients
  (n = 225)
Any illness
173
76.9%
Cytomegalovirus infection
93
41.3%
Pneumocystis jirovecii pneumonia
66
29.3%
Any bacterial pneumonia
31
13.8%
Aspergillus infection
23
10.2%
Kaposi sarcoma
21
9.3%
Non-tuberculous mycobacterium infection
14
6.2%
Cryptococcosis
11
4.9%
Candida infection
10
4.4%
Tuberculosis41.8%

Because more than one illness was detected in patients, the numbers of all illness are greater than the total number.

Table 5

Brain disease in patients infected with HIV

Illness
n
% in total autopsied brains
  (n = 172)
Any illness
85
49.4%
Cytomegalovirus infection
45
26.1%
Malignant lymphoma
26
15.1%
HIV encephalopathy
21
12.2%
Progressive multifocal leukoencephalopathy
8
4.7%
Toxoplasmosis
8
4.7%
Non-tuberculous mycobacterium infection
4
2.3%
Aspergillus infection
2
1.2%
Varicella zoster virus infection
2
1.2%
Herpes simplex virus infection
1
0.6%
Glioblastoma
1
0.6%
Candida infection10.6%

Because more than one illness was detected in patients, the numbers of all illness are greater than the total number.

Lung disease in patients infected with HIV Because more than one illness was detected in patients, the numbers of all illness are greater than the total number. Brain disease in patients infected with HIV Because more than one illness was detected in patients, the numbers of all illness are greater than the total number. We also investigated the direct causes of death in the autopsied patients (Table  6). Lymphoma was the most frequent cause of death, followed by CMV infection. Non AIDS-defining cancers as a cause of death were significantly different between ART (−) (2, 1.5%) and ART (+) patients (6, 9.1%) (P = 0.026; Chi-square test with Yates correction). The prevalence of CMV, pneumonia, PCP, and NTM as a cause of death were lower in ART (+) patients compared with ART (−) patients, but no significant differences were observed between the groups.
Table 6

Cause of death in AIDS-associated autopsies

 
All
ART (−) patients
ART (+) patients
 
 
 n%n%n% P values 
Total*
225
100.0%
136
100.0%
66
100.0%
 
 
Malignant lymphoma
50
22.2%
33
24.3%
16
24.2%
0.997
 
Cytomegalovirus
44
19.6%
27
19.9%
9
13.6%
0.279
 
Pneumonia
31
13.8%
19
14.0%
9
13.6%
0.949
 
Pneumocystis jirovecii pneumonia
30
13.3%
21
15.4%
4
6.1%
0.058
 
Non-tuberculous mycobacterium
12
5.3%
10
7.4%
2
3.0%
0.367
Y
Kaposi sarcoma
11
4.9%
7
5.1%
2
3.0%
0.749
Y
Progressive multifocal leukoencephalopathy
8
3.6%
4
2.9%
2
3.0%
0.684
Y
Cancer
8
3.6%
2
1.5%
6
9.1%
0.026
Y
Hepatitis
8
3.6%
3
2.2%
4
6.1%
0.320
Y
Cryptococcus
7
3.1%
6
4.4%
0
0.0%
0.197
Y
Kidney failure
7
3.1%
4
2.9%
3
4.5%
0.861
Y
HIV encephalopathy
7
3.1%
5
3.7%
2
3.0%
0.861
Y
Aspergillus
6
2.7%
5
3.7%
0
0.0%
0.274
Y
Toxoplasmosis
4
1.8%
3
2.2%
1
1.5%
0.835
Y
Tuberculosis
3
0.9%
2
1.5%
0
0.0%
0.816
Y
Sepsis
3
1.3%
2
1.5%
1
1.5%
0.551
Y
Candida
3
1.3%
2
1.5%
0
0.0%
0.816
Y
Varicella zoster virus
2
1.3%
1
0.7%
1
1.5%
0.816
Y
Nocardia
1
0.4%
1
0.7%
0
0.0%
0.711
Y
Histoplasma10.4%10.7%00.0%0.711Y

*Because more than one illness was detected in patients, the numbers of all illness are greater than the total number.

HIV, human immunodeficiency virus. P values were calculated with the Chi-square test. Y indicates the use of Chi-square test with Yates correction. Bold font indicates statistical significance.

Cause of death in AIDS-associated autopsies *Because more than one illness was detected in patients, the numbers of all illness are greater than the total number. HIV, human immunodeficiency virus. P values were calculated with the Chi-square test. Y indicates the use of Chi-square test with Yates correction. Bold font indicates statistical significance.

Discussion

In the present study, we measured the prevalence of infectious disease and malignancy in autopsy cases of HIV-infected patients identified from 1985–2012 at four central hospitals in Japan. CMV infection, PCP, NTM infection, NHL, and KS were frequently observed in the autopsy cases. The prevalence of CMV and PCP was lower in ART (−) patients compared with ART (+) patients. The prevalence of non-AIDS defining malignancies was higher among ART (+) patients than ART (−) patients, suggesting that the onset of various opportunistic infections and malignancies should be carefully monitored regardless of whether the patient is receiving ART. The autopsy cases in the present study were predominantly male (95.1%, Table  1). Additionally, more than 70% of the autopsy cases in the present study had a CD4 count < 200 cells/μL at the last blood examination before death (Table  1). A recent clinical study demonstrated the incidence of AIDS-defining illnesses in patients with HIV infection was decreased by the introduction of ART, especially in patients with CD4 counts >200 cells/μL [2]. Thus, our findings at autopsy cannot be compared with previous clinical studies because many clinical study patients had a high range of CD4 counts and ART responses. Interestingly, there was no significant difference in the cause of death between ART (+) and (−) patients, with the exception of those with cancer (Table  6), indicating the prevalence of lethal illness did not differ between ART (+) and (−) patients. Malignancies were frequent causes of death in the present study regardless of ART status (Table  6). Several studies demonstrated that the introduction of ART reduced the incidence of NHL in patients with HIV infection [13,15,19-23]. The use of ART has also been associated with a decrease in the incidence of KS [15,24,25]. However, an association between the incidence of non-AIDS-defining cancers and ART remains controversial. An increase of non-AIDS-defining cancers in patients receiving ART was shown in previous clinical reports [26,27], but a separate study showed that, with the exception of long-term protease inhibitor usage, ART exposure was generally not associated with a risk of non-AIDS-defining cancers [28]. The reasons for increased risk of non-AIDS-defining cancers in patients on ART are unclear, but might reflect the concomitant increase of the mean age at autopsy during the study period. This suggests that life extension of HIV-infected patients by ART results in the increased chance of developing non-AIDS events and malignancies. It was also demonstrated that ART introduction changed the pathological features of lymphoma; for example, a decrease of Epstein–Barr virus-positive lymphoma in Japanese patients with AIDS was reported [29]. Although HL was rare in the general Japanese population compared with European countries and the United States [30], the incidence of HL increased in Japanese patients on ART [17]. Thus, the increased risk of malignancies during the clinical course of HIV infection in patients receiving ART was reflected as a cause of death in the autopsy cases used in our study. The prevalence of opportunistic infections differs among various regions and countries. In sub-Saharan African countries, more than 80% of HIV-positive patients die of infectious diseases, with disseminated tuberculosis being the most common (36%) [31]. Furthermore, there was no difference in the type of disease HIV patients succumbed to, regardless of ART status. In the USA and European countries, tuberculosis/NTM represented <10% of mortality in autopsy cases after 1996 [18]. In this study, tuberculosis was detected in only 2.7% of Japanese autopsy cases, but was the cause of death for 50% of afflicted patients. Mortality by PCP has decreased worldwide in patients with AIDS owing to prophylactic administration of an anti-PCP drug [16]. PCP was found in 36.4% (36/99 cases) of patients with AIDS before 1997, but was significantly reduced after 1997 (23.8%; 30/126 cases; P = 0.04; Chi-square test). This suggests that the decrease in PCP cases is associated with ART and anti-PCP prophylaxis. Our study had several limitations. Bacterial culture was not available in this study owing to the use of formalin-fixed paraffin-embedded samples, and it was therefore difficult to identify the bacterial species responsible for many cases of pneumonia. Additionally, clinical information was limited. Information on HIV-RNA, an important indicator of ART effects, was not available for these patients. In addition, information regarding CD4 counts and the type, duration and possible interruption of ART were not available for a subset of patients. Therefore, we could not identify cases of immune reconstitution syndrome. Age at seroconversion and time living with HIV are also major predictors of HIV disease progression, however information of these parameters was limited. Thus, it should be noted that the conclusions in this study cannot be generally applied to the current HIV positive population in Japan. Furthermore, all findings in this study were obtained from autopsies.

Conclusions

Although further studies are required to demonstrate the association between ART and illness identified at autopsy, the present study demonstrates the prevalence of infectious diseases and malignancies in autopsy cases of HIV infection in Japan. While the prevalence of CMV infection and PCP at autopsy were lower in ART (+) patients than ART (−) patients, non-AIDS–defining malignancies were observed as a cause of death more frequently in ART (+) patients than ART (−) patients.

Abbreviations

HIV: Human immunodeficiency virus; ART: Antiretroviral therapy; AIDS: Acquired immunodeficiency syndrome; PCP: Pneumocystis jirovecii pneumonia; CMV: Cytomegalovirus; NTM: Non-tuberculous mycobacteria; NHL: Non-Hodgkin lymphoma; KS: Kaposi sarcoma.

Competing interests

The authors declare no conflicts of interests.

Authors’ contributions

HK, S Okada and AY conceived this study; TH, MM, YKod, NO, YO, SM, TI, HH, and HK performed the autopsies, pathological analyses and reviews; AA, KT, JT, YKi, TU, TS, TK, AI, and S Oka collected clinical data; HK analyzed the data, performed statistical analyses, and drafted the manuscript. All authors read and approved the final manuscript.

Pre-publication history

The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2334/14/229/prepub
  31 in total

1.  Changes in pathological findings at autopsy in AIDS cases for the last 15 years.

Authors:  E Masliah; R M DeTeresa; M E Mallory; L A Hansen
Journal:  AIDS       Date:  2000-01-07       Impact factor: 4.177

2.  Systemic non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy.

Authors:  Regis A Vilchez; Jeffrey L Jorgensen; Michael H Kroll
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

3.  Reduced incidence of Kaposi's sarcoma and of systemic non-hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy.

Authors:  M P Carrieri; C Pradier; P Piselli; M Piche; E Rosenthal; P Heudier; J Durant; Diego Serraino
Journal:  Int J Cancer       Date:  2003-01-01       Impact factor: 7.396

4.  Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy.

Authors:  O Kirk; C Pedersen; A Cozzi-Lepri; F Antunes; V Miller; J M Gatell; C Katlama; A Lazzarin; P Skinhøj; S E Barton
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

5.  The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.

Authors:  N J Ives; B G Gazzard; P J Easterbrook
Journal:  J Infect       Date:  2001-02       Impact factor: 6.072

6.  AIDS across Europe, 1994-98: the EuroSIDA study.

Authors:  A Mocroft; C Katlama; A M Johnson; C Pradier; F Antunes; F Mulcahy; A Chiesi; A N Phillips; O Kirk; J D Lundgren
Journal:  Lancet       Date:  2000-07-22       Impact factor: 79.321

7.  Delays and continuation of hospital visits among HIV-infected persons and AIDS cases in Japan.

Authors:  S Hashimoto; T Matsumoto; M Nagai; Y Matsuyama; Y Nakamura; T Umeda; M Kamakura; S Ichikawa; S Kimura; K Fukutomi; M Kihara
Journal:  J Epidemiol       Date:  2000-01       Impact factor: 3.211

Review 8.  Overview on the incidence and the characteristics of HIV-related opportunistic infections and neoplasms of the heart: impact of highly active antiretroviral therapy.

Authors:  Raffaele Bruno; Paolo Sacchi; Gaetano Filice
Journal:  AIDS       Date:  2003-04       Impact factor: 4.177

9.  The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era.

Authors:  A Mocroft; H J Furrer; J M Miro; P Reiss; C Mussini; O Kirk; S Abgrall; S Ayayi; B Bartmeyer; D Braun; A Castagna; A d'Arminio Monforte; B Gazzard; F Gutierrez; I Hurtado; K Jansen; L Meyer; P Muñoz; N Obel; P Soler-Palacin; A Papadopoulos; F Raffi; J T Ramos; J K Rockstroh; D Salmon; C Torti; J Warszawski; S de Wit; R Zangerle; C Fabre-Colin; J Kjaer; G Chene; J Grarup; J D Lundgren
Journal:  Clin Infect Dis       Date:  2013-08-06       Impact factor: 9.079

10.  Trends in mortality from Hodgkin's disease in western and eastern Europe.

Authors:  F Levi; F Lucchini; E Negri; P Boyle; C La Vecchia
Journal:  Br J Cancer       Date:  2002-07-29       Impact factor: 7.640

View more
  11 in total

Review 1.  COVID-19-associated opportunistic infections: a snapshot on the current reports.

Authors:  Amir Abdoli; Shahab Falahi; Azra Kenarkoohi
Journal:  Clin Exp Med       Date:  2021-08-23       Impact factor: 5.057

2.  Prevalence and Correlates of Reporting Difficulty Taking Antiretroviral Treatment Among HIV-Positive Illicit Drug Users in Vancouver, Canada: A Longitudinal Analysis.

Authors:  Bianca Yeung; N A Mohd Salleh; Eugenia Socías; Huiru Dong; J Shoveller; J S G Montaner; M-J S Milloy
Journal:  AIDS Behav       Date:  2019-05

3.  Prevalence and Patterns of Multimorbidity among Human Immunodeficiency Virus Positive People in Odisha, India: An Exploratory Study.

Authors:  Sanghamitra Pati; Shreeporna Bhattacharya; Subhashisa Swain
Journal:  J Clin Diagn Res       Date:  2017-06-01

4.  Changing Spectrum of Opportunistic Illnesses among HIV-Infected Taiwanese Patients in Response to a 10-Year National Anti-TB Programme.

Authors:  Chun-Yuan Lee; Pei-Hua Wu; Po-Liang Lu; Hung-Chin Tsai
Journal:  J Clin Med       Date:  2019-02-01       Impact factor: 4.241

5.  Cytopathological analysis of bronchoalveolar lavage fluid in patients with and without HIV infection.

Authors:  Xiang-Mei Chen; Lei Sun; Kun Yang; Jia-Min Chen; Liang Zhang; Xiao-Yi Han; Xingang Zhou; Zhi-Yuan Ma; Man Li; Hong-Xin Zhao; Li-Ming Qi; Peng Wang
Journal:  BMC Pulm Med       Date:  2022-02-08       Impact factor: 3.317

6.  Spectrum of Opportunistic Infections and Risk Factors for In-Hospital Mortality of Admitted AIDS Patients in Shanghai.

Authors:  Bin Luo; Jianjun Sun; Rentian Cai; Yinzhong Shen; Li Liu; Jiangrong Wang; Renfang Zhang; Jiayin Shen; Hongzhou Lu
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

7.  Opportunistic Infections in HIV-Infected Patients Differ Strongly in Frequencies and Spectra between Patients with Low CD4+ Cell Counts Examined Postmortem and Compensated Patients Examined Antemortem Irrespective of the HAART Era.

Authors:  Marta K Powell; Kamila Benková; Pavel Selinger; Marek Dogoši; Iva Kinkorová Luňáčková; Hana Koutníková; Jarmila Laštíková; Alena Roubíčková; Zuzana Špůrková; Lucie Laclová; Václav Eis; Josef Šach; Petr Heneberg
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

8.  Comorbidities and the use of comedications in people living with HIV on antiretroviral therapy in Japan: a cross-sectional study using a hospital claims database.

Authors:  Daniel J Ruzicka; Kentaro Imai; Kenichi Takahashi; Toshio Naito
Journal:  BMJ Open       Date:  2018-06-14       Impact factor: 2.692

9.  Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation.

Authors:  Iain D Page; Rosemary Byanyima; Sharath Hosmane; Nathan Onyachi; Cyprian Opira; Malcolm Richardson; Richard Sawyer; Anna Sharman; David W Denning
Journal:  Eur Respir J       Date:  2019-03-18       Impact factor: 16.671

Review 10.  Advances in Oncology in US and Japan: Focusing on Cancer and Infectious Diseases.

Authors:  Hiroto Nakano; Takuto Miyamoto; Yelena Y Janjigian; Sohtaro Mine; Hiroaki Mitsuya; Naoto T Ueno; Elad Sharon; Shunsuke Sakai; William C Timmer; Shuichiro Nakabo; Tomoko Ikeuchi; Saori Fujiwara; Minori Kinjo; Tadashi Inuzuka; Hayato Kume; Keisuke Shirai; Norihiro Yamaguchi; Kazuaki Takabe; Naoko Takebe
Journal:  World J Oncol       Date:  2021-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.